GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Orthofix Medical Inc (NAS:OFIX) » Definitions » 3-Year Sharpe Ratio

OFIX (Orthofix Medical) 3-Year Sharpe Ratio : -0.46 (As of Jul. 05, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Orthofix Medical 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-05), Orthofix Medical's 3-Year Sharpe Ratio is -0.46.


Competitive Comparison of Orthofix Medical's 3-Year Sharpe Ratio

For the Medical Devices subindustry, Orthofix Medical's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orthofix Medical's 3-Year Sharpe Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Orthofix Medical's 3-Year Sharpe Ratio falls into.


;
;

Orthofix Medical 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Orthofix Medical  (NAS:OFIX) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Orthofix Medical 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Orthofix Medical's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Orthofix Medical Business Description

Traded in Other Exchanges
Address
3451 Plano Parkway, Lewisville, TX, USA, 75056
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Executives
Geoffrey C Gillespie officer: VP, Controller, Interim CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Puja Leekha officer: CECO & Interim CLO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kevin J. Kenny officer: President of Global Spine C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John J. Bostjancic officer: CFO C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Keith Valentine director, officer: President & CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Patrick L Keran officer: Chief Legal Officer 6725 MESA RIDGE RD., SUITE 100, SAN DIEGO CA 92121
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael E Paolucci director 7475 LUSK BLVD., SAN DIEGO CA 92121
Catherine M Burzik director
Rice Doug officer: CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kimberley A. Elting officer: Chief Legal Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056